Differences in clinical presentation and outcome between immune checkpoint inhibitor-associated myocarditis and classical acute myocarditis: Same disease, distinct challenges to face

Immune checkpoint inhibitors (ICI) are new cancer drugs that target immune checkpoints, molecules acting as regulators of the immune system, boosting the immune response against cancer cells. Currently approved ICI block cytotoxic T-lymphocyte antigen-4 and programmed death (PD)-1 and PD ligand-1. Since their introduction in cancer therapy, ICI had great impact on treatment and prognosis of different cancers. As highlighted by US estimates, ICI are increasingly being used in cancer population, with the percentage of eligible patients for ICI increasing from 1.5% in 2011 to 43.6% in 2018 [1].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research